Substance / Medication

Lactulose

Overview

Active Ingredient
lactulose
RxNorm CUI
6218

Indications

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Labeler: Chartwell RX, LLCUpdated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Since lactulose solution contains galactose (less than 1.6 g/15 mL), it is contraindicated in patients who require a low galactose diet.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
Moon Andrew M, Kim Hannah P, Jiang Yue et al. · Am J Gastroenterol · 2023
PMID: 36730910Meta-AnalysisFull text (PMC)
Prophylactic Lactulose Therapy in Patients with Cirrhosis and Upper Gastrointestinal Bleeding: A Meta-analysis of Randomized Trials.
Roy Akash, Giri Suprabhat, Singh Ankita et al. · J Gastrointestin Liver Dis · 2023
PMID: 38147599Meta-Analysis
A case for improved assessment of gut permeability: a meta-analysis quantifying the lactulose:mannitol ratio in coeliac and Crohn's disease.
Gan Jonathan, Nazarian Scarlet, Teare Julian et al. · BMC Gastroenterol · 2022
PMID: 35012471Meta-AnalysisFull text (PMC)
Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis.
Hoilat Gilles Jadd, Ayas Mohamad Fekredeen, Hoilat Judie Noemie et al. · BMJ Open Gastroenterol · 2021
PMID: 34006606Meta-AnalysisFull text (PMC)
Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
Wang Zhida, Chu Pei, Wang Wenjin · Drug Des Devel Ther · 2019
PMID: 30587923Meta-AnalysisFull text (PMC)
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud Lise Lotte, Vilstrup Hendrik, Morgan Marsha Y · Cochrane Database Syst Rev · 2016
PMID: 27089005Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lactulose (substance)
SNOMED CT
273945008
UMLS CUI
C0022957
RxNorm CUI
6218
Labeler
Chartwell RX, LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.